Unlocking the potential of targeted protein degradation via nanoparticle-based universal strategy
Open Access
- 13 September 2025
- journal article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 6082-6086
Abstract
No abstract availableKeywords
Funding Information
- Fundamental Research Funds for the Central Universities (2022CX01013)
- National Natural Science Foundation of China (32171394)
- National Natural Science Foundation of China (U23A20489)
- China Postdoctoral Science Foundation (2023M740259)
- China Postdoctoral Science Foundation (2024M761233)
This publication has 9 references indexed in Scilit:
- Optimizing TPD-based oncology drug development: the critical role of PDR distribution in POI-positive cancer cellsActa Pharmaceutica Sinica B, 2025
- A covalent peptide-based lysosome-targeting protein degradation platform for cancer immunotherapyNature Communications, 2025
- SnapShot: Targeted protein degradationCell, 2024
- Targeted protein degradation via cellular trafficking of nanoparticlesNature Nanotechnology, 2024
- Drug delivery pathways to the central nervous system via the brain glymphatic system circumventing the blood‐brain barrierExploration, 2024
- Targeted protein degradation: from mechanisms to clinicNature Reviews Molecular Cell Biology, 2024
- Expanding the horizons of targeted protein degradation: A non-small molecule perspectiveActa Pharmaceutica Sinica B, 2024
- Antibody targeting of E3 ubiquitin ligases for receptor degradationNature, 2022
- The PROTAC gold rushNature Biotechnology, 2021